Bilal Arif joined Sarepta in 2019 as senior vice president, head of strategy and technical operations where he was central in helping grow the technical operations team and building the Company’s manufacturing capabilities. He was named chief technical operations officer in December 2022. As head of technical operations, Bilal is responsible for the Company’s CMC strategy and global supply chain management for its RNA and gene therapy portfolio.
Having dedicated his entire career to the strategic and operational aspects of manufacturing, Bilal is a well-regarded and recognized leader with over 20 years of relevant biotech, pharma and management experience, including serving as vice president, product strategy & planning, technical operations at Shire. During his tenure at Shire, Bilal served as a member of the technical operations leadership team. His experience spans across supporting early clinical-stage programs through to market authorization. At Shire, Bilal was also responsible for leading the TechOps team responsible for conducting due diligence/integration of new technologies and M&A assets.
“My interest in manufacturing and technical operations is matched by my desire to be a part of the most exciting and promising areas of scientific innovation, which was the primary driver for joining Sarepta. I love the pace, which supports the idea that we are truly dragging tomorrow into today for patients. For these reasons and many more, being at Sarepta in this role and at this time, has been and continues to be a real highlight of my career.”
In touching upon his vision for Sarepta’s CMC strategy, Bilal cited proactive management, preparedness, quick decision making, and recognizing the importance of teamwork as being a promising formula for success.
“Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team.”
Bilal received his Bachelor of Engineering degree in chemical engineering from McGill University, a Master of Science in Biotechnology from Tufts University, and an MBA from Brown University’/Instituto de Empresa (IE) Business School.
What is Bilal Arif's net worth?
The estimated net worth of Bilal Arif is at least $2.59 million as of June 24th, 2024. Mr. Arif owns 21,261 shares of Sarepta Therapeutics stock worth more than $2,591,716 as of December 26th. This net worth evaluation does not reflect any other investments that Mr. Arif may own. Learn More about Bilal Arif's net worth.
How old is Bilal Arif?
Mr. Arif is currently 52 years old. There are 4 older executives and no younger executives at Sarepta Therapeutics. The oldest executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who is 61 years old. Learn More on Bilal Arif's age.
How do I contact Bilal Arif?
Has Bilal Arif been buying or selling shares of Sarepta Therapeutics?
Bilal Arif has not been actively trading shares of Sarepta Therapeutics during the past quarter. Most recently, Bilal Arif sold 7,859 shares of the business's stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a transaction totalling $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares of the company's stock, valued at $3,467,243.88. Learn More on Bilal Arif's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
